Article Versions Notes

Wu J-C, Chuang Y-H, Wei Y-C, Hsieh C-C, Pong Y-H, Su Y-R, Tsai VF-S, Wu G-J. Validating METCAM/MUC18 as a Novel Biomarker to Predict the Malignant Potential of Prostate Cancer at an Early Stage by Using a Modified Gold Nanoparticles-Based Lateral Flow Immunoassay. Diagnostics. 2021; 11(3):443. https://doi.org/10.3390/diagnostics11030443

Wu, Jui-Chuang, Yin-Huan Chuang, Yu-Chun Wei, Chia-Chi Hsieh, Yuan-Hung Pong, Yenn-Rong Su, Vincent F.-S. Tsai, and Guang-Jer Wu. 2021. "Validating METCAM/MUC18 as a Novel Biomarker to Predict the Malignant Potential of Prostate Cancer at an Early Stage by Using a Modified Gold Nanoparticles-Based Lateral Flow Immunoassay" Diagnostics 11, no. 3: 443. https://doi.org/10.3390/diagnostics11030443

Wu, J.-C., Chuang, Y.-H., Wei, Y.-C., Hsieh, C.-C., Pong, Y.-H., Su, Y.-R., Tsai, V. F.-S., & Wu, G.-J. (2021). Validating METCAM/MUC18 as a Novel Biomarker to Predict the Malignant Potential of Prostate Cancer at an Early Stage by Using a Modified Gold Nanoparticles-Based Lateral Flow Immunoassay. Diagnostics, 11(3), 443. https://doi.org/10.3390/diagnostics11030443